Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference, held September 8-10, 2026, in Boston, MA. One-on-one meetings are scheduled for Thursday, September 10, 2026, and interested parties are asked to contact their Wells Fargo representative to arrange a meeting.
Details
News Market Reaction – ELTX
On Aug 24, the day this news came out, ELTX closed 1.97% below the previous close. Relative volume reached 3.4x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 24 session.
Key Figures
- Conference edition
- 21st annual
- Wells Fargo Healthcare Conference
- Conference dates
- September 8-10, 2026
- Wells Fargo Healthcare Conference in Boston
- Meeting date
- September 10, 2026
- One-on-one meetings with management
- Meeting format
- 1×1
- One-on-one meetings
Historical Context
-
Phase 2 primary endpoint miss outweighed reported complete responses and planned combination study.
-
Neoadjuvant study activation preceded a negative 24-hour price reaction.
-
Offering closing preceded a 15.02% negative 24-hour reaction.
-
Offering pricing preceded a 37.35% negative 24-hour reaction.
-
Russell 2000 and Russell 3000 additions produced a zero price reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
kras medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
Wells Fargo 21st Annual Healthcare Conference
Format: One-on-one Meetings
Date: Thursday, September 10, 2026
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.